Publications by authors named "Edward B Garon"

Claim this Profile
R
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated -Mutated Metastatic NSCLC.
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Kazuto Nishio

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma.
Morgan R Brady, Nedas Matulionis, Heather R Christofk, Edward B Garon, Aaron Lisberg

Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in Clinical Trial Availability vs Distribution of Disease Among Gynecological Cancers.
Andrea I Nañez Md, Maria A Velez, Mae Zakhour Md, Edward B Garon

Oncology (Williston Park)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in , or : the TRITON study.
Ferdinandos Skoulidis, Hossein Borghaei, Edward B Garon, Ticiana A Leal, Jacob Kaufman

Ther Adv Med Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer.
Sara Sakowitz, Haley I Tupper, Lawrence N Benjamin, Scott Oh, Tao He, Edward B Garon

Chest· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework.
Maria J Fernandez Turizo, Maria A Velez, Beth Glenn, Amy L Cummings, Barbara Segarra-Vazquez, Edward B Garon

Oncologist· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431].
Marina C Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip, Edward B Garon

JTO Clin Res Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
Martin Reck, Jyoti D Patel, Jhanelle E Gray, Noemí Reguart, Manuel Cobo, Edward B Garon

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Targetable Mutations in Ovarian Cancer.
Arjan Gower, Susan Win, Rituparna Ganguly, Melissa Johnson, Maria A Velez, Edward B Garon

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer.
Drew Moghanaki, Emily A Cameron, Edward B Garon

Lung Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.
Michael S Oh, Edward B Garon, Aaron E Lisberg, Amy L Cummings, Alex Barrett

Clin Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring After Therapy.
Maria A Velez, Elliot S Kang, Chester A Thompson, Jackson Lind-Lebuffe, Collin Shen, Edward B Garon

JCO Oncol Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated -Mutated Metastatic NSCLC: RELAY Japanese Subset.
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Kazuto Nishio

JTO Clin Res Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix

J Thorac Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Edward B Garon

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer.
Michael S Oh, Camelia Dumitras, Ramin Salehi-Rad, Linh M Tran, Kostyantyn Krysan, Edward B Garon

Mol Cancer Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Solange Peters, Byoung Chul Cho, Alexander V Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Edward B Garon

J Thorac Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B Garon, Koichi Goto

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Edward B Garon

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, Noemi Reguart, Pierre-Jean Souquet, Edward B Garon

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
Ariane Lozac'hmeur, Tyler Danek, Qidi Yang, Mario G Rosasco, John S Welch, Edward B Garon

NPJ Precis Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sleep Disturbance as a Mediator of Lung Cancer Stigma on Psychological Distress and Physical Symptom Burden.
Timothy J Williamson, Edward B Garon, Michael R Irwin, Alyssa K Choi, Jonathan W Goldman

Psychosom Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Edward B Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater

Clin Lung Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RELAY, Erlotinib Plus Ramucirumab in Untreated, -Mutated, Metastatic NSCLC: Outcomes by Exon 19 Deletion Variants.
Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B Garon

JTO Clin Res Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlights in non-small cell lung cancer from the IASLC 2023 World Conference on Lung Cancer: commentary.
Edward B Garon

Clin Adv Hematol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis